Newly Synthesized Fluorinated Cinnamylpiperazines Possessing Low In Vitro MAO-B Binding.
MAO-B
cinnamic acid
piperazine
positron emission tomography
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
26 Oct 2020
26 Oct 2020
Historique:
received:
17
08
2020
revised:
06
10
2020
accepted:
23
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
31
3
2021
Statut:
epublish
Résumé
Herein, we report on the synthesis and pharmacological evaluation of ten novel fluorinated cinnamylpiperazines as potential monoamine oxidase B (MAO-B) ligands. The designed derivatives consist of either cinnamyl or 2-fluorocinnamyl moieties connected to 2-fluoropyridylpiperazines. The three-step synthesis starting from commercially available piperazine afforded the final products in overall yields between 9% and 29%. An in vitro competitive binding assay using l-[
Identifiants
pubmed: 33114548
pii: molecules25214941
doi: 10.3390/molecules25214941
pmc: PMC7663645
pii:
doi:
Substances chimiques
Piperazine
1RTM4PAL0V
Monoamine Oxidase
EC 1.4.3.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutscher Akademischer Austauschdienst
ID : 57391403
Organisme : Ministry of Education, Science and Technological Development, Republic of Serbia
ID : 451-03- 01732/2017-09/4
Références
Eur J Nucl Med. 1998 May;25(5):464-70
pubmed: 9575241
Bioorg Chem. 2015 Oct;62:22-9
pubmed: 26189013
Proteins. 2003 Sep 1;52(4):609-23
pubmed: 12910460
Bioorg Med Chem. 2017 Jul 15;25(14):3638-3648
pubmed: 28529043
FASEB J. 1995 May;9(8):605-10
pubmed: 7768351
EJNMMI Radiopharm Chem. 2017;1(1):13
pubmed: 29564389
Trends Pharmacol Sci. 2009 Aug;30(8):431-40
pubmed: 19616318
Med Res Rev. 2019 Sep;39(5):1603-1706
pubmed: 30604512
J Enzyme Inhib Med Chem. 2017 Dec;32(1):776-788
pubmed: 28585866
Molecules. 2015 Oct 09;20(10):18387-421
pubmed: 26473809
Bioorg Chem. 2020 Apr;97:103707
pubmed: 32146176
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1042-1050
pubmed: 28120003
J Med Chem. 2009 Nov 12;52(21):6685-706
pubmed: 19810674
J Med Chem. 2015 Sep 24;58(18):7465-74
pubmed: 26288158
J Med Chem. 2018 May 24;61(10):4528-4560
pubmed: 29664627
Bioconjug Chem. 2015 Jan 21;26(1):1-18
pubmed: 25473848
J Med Chem. 2015 Nov 12;58(21):8315-59
pubmed: 26200936
Mol Psychiatry. 2016 Nov;21(11):1499-1503
pubmed: 27480491
J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):78-88
pubmed: 24285313
Eur J Med Chem. 2017 Jan 27;126:1056-1070
pubmed: 28027531
J Chem Inf Model. 2009 Oct;49(10):2344-55
pubmed: 19788294
Neurochem Int. 2008 Jan;52(1-2):230-4
pubmed: 17624626
J Neurosci. 1992 May;12(5):1977-99
pubmed: 1578281
Chem Pharm Bull (Tokyo). 2017;65(11):1020-1027
pubmed: 29093288
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1369-1382
pubmed: 30919054
Neurobiol Aging. 1997 Jul-Aug;18(4):431-5
pubmed: 9330975
Nucl Med Biol. 2006 Feb;33(2):161-4
pubmed: 16546669
Sci Rep. 2015 Nov 10;5:16404
pubmed: 26553227
Org Lett. 2015 Dec 4;17(23):5780-3
pubmed: 26568457
Bioorg Med Chem Lett. 2019 Jul 1;29(13):1624-1627
pubmed: 31060887
Nat Rev Neurosci. 2006 Apr;7(4):295-309
pubmed: 16552415
Prog Drug Res. 1992;38:171-297
pubmed: 1609114
Mol Imaging Biol. 2005 Nov-Dec;7(6):377-87
pubmed: 16265597
Biochem Biophys Res Commun. 2007 Aug 24;360(2):401-6
pubmed: 17597580
J Med Chem. 2015 Sep 10;58(17):6717-32
pubmed: 25915162
J Neurol Sci. 2007 Apr 15;255(1-2):17-22
pubmed: 17346749
Handb Clin Neurol. 2018;154:251-266
pubmed: 29903443
Neurochem Int. 2011 Jan;58(1):60-8
pubmed: 21075154
Front Neurosci. 2016 Jun 10;10:265
pubmed: 27375423
Curr Med Chem. 2002 Jul;9(13):1303-21
pubmed: 12052168
Molecules. 2018 Apr 28;23(5):
pubmed: 29710787
Bioorg Chem. 2018 Apr;77:252-262
pubmed: 29421700
Parkinsonism Relat Disord. 2000 Jan;6(1):25-47
pubmed: 18591148